GSK, Imperial College London and the University of Oxford announced the Modelling‑Informed Medicine Centre (MiMeC), an £11 million initiative to build open‑source digital twins of lungs, liver and kidneys for drug development. The center will integrate mechanistic models, AI and multi‑scale data to run virtual experiments and inform target selection, dosing and trial design. MiMeC aims to embed organ models into GSK’s R&D pipeline within five years and provide industrial placements to train modeling‑informed medicine experts. For drug developers, validated digital twins could shorten preclinical testing, de‑risk translation and enable precision dosing strategies — but they will require robust validation against clinical datasets and regulatory acceptance.